Creating new mouse models to find treatments for cognitive issues in Down syndrome related to Alzheimer's disease
Generation and analysis of new mouse models to determine novel therapeutic targets for Down syndrome-associated cognitive deficits
['FUNDING_R01'] · ROSWELL PARK CANCER INSTITUTE CORP · NIH-10937797
This study is looking at how Alzheimer's disease impacts thinking and memory in people with Down syndrome, using specially modified mice to find new ways to help improve their cognitive abilities.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ROSWELL PARK CANCER INSTITUTE CORP (nih funded) |
| Locations | 1 site (BUFFALO, UNITED STATES) |
| Trial ID | NIH-10937797 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the complex relationship between Down syndrome and Alzheimer's disease, particularly how Alzheimer's affects cognitive function in individuals with Down syndrome. Using advanced CRISPR technology, researchers will create genetically modified mice to study the roles of specific proteins involved in Alzheimer's pathology. By investigating these molecular mechanisms, the goal is to identify potential therapeutic targets that could lead to effective treatments for cognitive deficits associated with Down syndrome and Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with Down syndrome, particularly those who are at risk of developing Alzheimer's disease as they age.
Not a fit: Patients without Down syndrome or those who do not have cognitive deficits related to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve cognitive function and quality of life for individuals with Down syndrome who are affected by Alzheimer's disease.
How similar studies have performed: Previous research has shown promise in using genetic models to explore Alzheimer's disease mechanisms, indicating that this approach could yield valuable insights.
Where this research is happening
BUFFALO, UNITED STATES
- ROSWELL PARK CANCER INSTITUTE CORP — BUFFALO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YU, EUGENE — ROSWELL PARK CANCER INSTITUTE CORP
- Study coordinator: YU, EUGENE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer Disease 1 Protein, Alzheimer Disease Protease Nexin-II, Alzheimer disease dementia